https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-issues-form-483-with-two-observations-for-lupins-nagpur-plant/articleshow/101713660.cms
0
0
7/13/23 at 3:00am
Organization
The Times of India
Author
ET Online
61 words
0
Comments
Lupin's Nagpur facility has received two observations from the USFDA through Form-483 due to violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company assured that it would resolve the issues raised and is confident of doing so soon. T…
You are the first to view
Create an account
or login to join the discussion